Business
Lexington Biosciences Receives HeartSentry Trial Units
Lexington Biosciences Receives HeartSentry Trial Units.
About this update from Lexington Biosciences Inc
[{"type":"text","content":"\n \n \n Lexington Biosciences Receives HeartSentry Trial Units\n \n \nLexington Biosciences Receives HeartSentry Trial Units\n \n VANCOUVER, BRITISH COLUMBIA--(Marketwired - Oct 23, 2017) - Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF) (the \"Company\" or \"Lexington\"), a development-stage medical device company, is pleased to announce receipt of the first HeartSentry human-use units from its manufacturer. \n Company President Eric Willis comments, \"We are delighted to take delivery of these first HeartSentry human-use units from our manufacturer. The design and production team have worked for nine months to perfect the HeartSentry technology and device design, and we have achieved a significant milestone by moving the HeartSentry out of the lab and into a hand-held mobile unit ready for clinical trials. We look forward to being able to commence study enrollment in our upcoming HeartSentry clinical study in order to gather the foundational dataset aimed at supporting FDA clearance. To find out more about Lexington Biosciences, I invite interested readers to visit our website and view our video featuring the principal HeartSentry inventor, Dr. Jonathan Maltz, Ph.D., which provides an excellent overview of our business proposition and opportunity ahead.\" \n About Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF)\n Lexington Biosciences is a medical device company developing the HeartSentry, a new non-invasive diagnostic device to measure and monitor cardiovascular health by assessing the function of a person's vascular endothelium - the vital innermost lining of a person's cardiovascular system. Currently, the standard of care is measurement using expensive external ultrasound by a highly trained technician. The HeartSentry core technology was developed at the University of California Berkeley over a fifteen-year R&D period involving many research studies and product iterations resulting in portfolio of multiple pending and issued patents licensed to the company. By taking delivery of the clinical trial ready HeartSentry units the company will commence studies as soon as possible. Our aim is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a pe...